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introduction: Autoantibodies to cytosolic 5 -nucleotidase 1A (cN-1A; NT5C1A) have a 
high specificity when differentiating sporadic inclusion body myositis from polymyositis and 
dermatomyositis. In primary Sjögren’s syndrome (pSS) and systemic lupus erythematosus 
(SLE) anti-cN-1A autoantibodies can be detected as well. However, various frequencies 
of anti-cN-1A reactivity have been reported in SLE and pSS, which may at least in part be 
explained by the different assays used. Here, we determined the occurrence of anti-cN-1A 
reactivity in a large number of patients with pSS and SLE using one standardized ELISA.
Methods: Sera from pSS (n = 193) and SLE patients (n = 252) were collected in five 
European centers. Anti-cN-1A, anti-Ro52, anti-nucleosome, and anti-dsDNA reactivities 
were tested by ELISA (Euroimmun AG) in a single laboratory. Correlations of anti-cN-1A 
reactivity with demographic data and clinical data (duration of disease at the moment of 
serum sampling, autoimmune comorbidity and presence of muscular symptoms) were 
analyzed using SPSS software.
results: Anti-cN-1A autoantibodies were found on average in 12% of pSS patients, 
with varying frequencies among the different cohorts (range: 7–19%). In SLE patients, 
the anti-cN-1A positivity on average was 10% (range: 6–21%). No relationship was 
found between anti-cN-1A reactivity and the presence or absence of anti-Ro52, anti- 
nucleosome, and anti-dsDNA reactivity in both pSS and SLE. No relationship between 
anti-cN-1A reactivity and duration of disease at the moment of serum sampling and 
the duration of serum storage was observed. The frequency of muscular symptoms or 
′
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viral infections did not differ between anti-cN-1A-positive and -negative patients. In both 
disease groups anti-cN-1A-positive patients suffered more often from other autoimmune 
diseases than the anti-cN-1A-negative patients (15 versus 5% (p = 0.05) in pSS and 50 
versus 30% (p = 0.02) in SLE).
conclusion: Our results confirm the relatively frequent occurrence of anti-cN-1A in 
pSS and SLE patients and the variation in anti-cN-1A reactivity between independent 
groups of these patients. The explanation for this variation remains elusive. The correla-
tion between anti-cN-1A reactivity and polyautoimmunity should be evaluated in future 
studies. We conclude that anti-cN-1A should be classified as a myositis-associated-, 
not as a myositis-specific-autoantibody based on its frequent presence in SLE and pSS.
Keywords: cytosolic 5′-nucleotidase 1a, anti-cn-1a, nT5c1a, autoantibodies, inclusion body myositis, sjögren’s 
syndrome, systemic lupus erythematosus
inTrODUcTiOn
Autoantibodies are often helpful in the diagnosis and follow up 
of patients with inflammatory myopathies. Traditionally these 
antibodies are characterized as myositis-specific (MSA) or myositis-
associated antibodies (MAA), according to their specificity. In 
2013, two independent research groups described a novel antibody 
in sporadic inclusion body myositis (IBM): anti-cytosolic 5′- 
nucleotidase 1A (anti-cN-1A; anti-NT5C1A) (1, 2). cN-1A is an 
enzyme involved in the conversion of adenosine monophosphate 
to adenosine, and it has a role in the dephosphorylation of nucleo-
tides to nucleosides (1). IBM is a slowly progressive muscle disease 
with a late onset. Its cause is yet unknown; inflammation, degen-
eration, and mitochondrial dysfunction all seem to play a role in 
the pathogenesis of IBM. Anti-cN-1A is present in 33–76% of IBM 
patients, and the variation is probably not only due to differences 
between cohorts, but is also dependent on the detection method 
and cutoff values that are used (1). Anti-cN-1A testing can improve 
the diagnostic process in IBM, and it can be used as a marker of 
expected disease severity. Anti-cN-1A positive IBM patients have 
more pronounced bulbar weakness and a higher mortality rate 
(2, 3). The presence or absence of anti-cN-1A antibodies in IBM 
is not related to the duration of symptoms or to the presence or 
absence of other autoimmune diseases or other autoantibodies 
(2). The specificity of anti-cN-1A antibodies has been established 
in previous studies. In healthy controls and in patients with poly-
myositis, dermatomyositis, and other neurological diseases, the 
prevalence of anti-cN-1A is low (0–4%) (4). However, in the sys-
temic autoimmune diseases primary Sjögren’s syndrome (pSS) and 
systemic lupus erythematosus (SLE) anti-cN-1A autoantibodies 
have been detected at various frequencies with different methods 
of detection (4–7). We aimed to establish the occurrence of anti-
cN-1A reactivity in multiple independent groups of European pSS 
and SLE patients using a single standardized detection method.
MaTerials anD MeThODs
Patients
Sera from pSS (n = 193) and SLE patients (n = 252) were collected 
in five different European centers: Tolmezzo, Italy; Strasbourg, 
France; Utrecht, The Netherlands; Malmö, Sweden and 
Copenhagen, Denmark. The patients were enrolled in biobanks 
in each of the participating centers, for which ethical permission 
was obtained. The SLE patients were diagnosed using the 1997 
American College of Rheumatology criteria; pSS patients ful-
filled the American-European Consensus Classification Criteria 
(8, 9). Demographic data (age and sex of the patient), clinical data 
(duration of disease at the moment of serum sampling, autoim-
mune co-morbidity, and presence of muscular symptoms) and 
the total duration of storage of the sample were retrieved from the 
respective biobank databases by the local researcher blinded for 
anti-cN-1A status. Muscular symptoms were defined as myalgia 
and muscle weakness, autoimmune comorbidity was defined 
as the presence of any other autoimmune disease. Patients with 
Sjögren’s syndrome secondary to SLE were classified as SLE.
laboratory analysis
Anti-cN-1A, anti-dsDNA, anti-nucleosomes, and anti-Ro52 reac-
tivities were tested by ELISA in a single laboratory. The anti-cN-1A, 
anti-dsDNA-NcX, and anti-nucleosomes ELISA are commercially 
available ELISAs and were performed according to the manufac-
turer’s instructions (respective order numbers EA 1675-4801G, 
EA 1572-9601G, and EA 1574-9601G, Euroimmun AG, Lübeck, 
Germany). The anti-cN-1A ELISA is based on recombinant 
full-length cN-1A antigen as described earlier (7). Results were 
evaluated semi-quantitatively as a ratio (optical density (OD) 450 
sample/OD450 calibrator, ratio ≥ 1 positive). The anti-dsDNA-NcX 
ELISA utilizes native dsDNA (isolated from calf thymus) as anti-
gen, which is immobilized via highly purified mononucleosomes 
free of histone H1, Scl-70, and other non-histone components 
(cutoff: ≥ 100 IU/ml) (10). The anti-nucleosomes ELISA is based 
on native mononucleosomes free of histone H1, Scl-70 and non-
histone components (cutoff: ≥ 20 RU/ml) (11).
Determination of anti-Ro52 reactivity was performed using 
an in-house ELISA (Euroimmun). Microtiter plates (Nunc, 
Denmark) were coated with 1 µg/ml recombinant Ro52 in PBS, 
pH 7.5 overnight at 4°C, washed with PBS-0.05% (w/v) Tween-
20, and blocked for 2 h with PBS-0.1% (w/v) casein, followed by 
washing. Sera diluted 1:200 in PBS-0.1% (w/v) casein were incu-
bated for 30 min before washing. Bound antibodies were detected 
Table 2 | Clinico-demographic correlations: anti-cN-1A in systemic lupus 
erythematosus (SLE).
sle anti-cn-1a 
positive  
10% (26/252)
anti-cn-1a 
negative  
90% (226/252)
p-Value
Provenance of the serum 0.03a
 – Italy
 – The Netherlands
 – France
 – Denmark
6%
12%
21%
6%
94%
88%
79%
94%
Female/male 10%/17% 91%/83% 0.27
Presence of muscular 
complaintsb
0% (0/19) 1% (2/160) 1.0
Presence of autoimmune 
co-morbidityc (number  
of patients)
46% (11/24) 30% (58/195) 0.02a
 – sSS
 – Antiphospholipid syndrome
 – Rheumatoid arthritis
 – Other
 – Combination
 – 15% (4)
 – 19% (5)
 – 12% (3)
 – 0% (0)
 – 0% (0)
 – 5% (10)
 – 19% (38)
 – 2% (4)
 – 2% (4)
 – 1% (2)
Presence of current or past  
viral infectiond
9% (2/23) 6% (10/177) 0.88
Presence of other antibodies
 – dsDNA
 – anti-nucleosomes
 – Ro52
31% (8/26)
23% (6/26)
42% (11/26)
39% (88/226)
31% (71/226)
32% (73/226)
0.52
0.50
0.38
aStatistically significant (p ≤ 0.05).
bMissing data in 29% of patients.
cMissing data in 13% of patients.
dMissing data in 21% of patients.
Table 1 | Clinico-demographic correlations: anti-cN-1A in primary Sjögren’s 
syndrome (pSS).
pss anti-cn-1a 
positive 12% 
(23/193)
anti-cn-1a 
negative 88% 
(170/193)
p-Value
Provenance of the serum 0.21
 – Italy
 – The Netherlands
 – France
 – Sweden
7%
8%
19%
15%
93%
92%
81%
85%
Female/male 12%/18% 88%/82% 0.63
Presence of muscular complaintsb 33% (4/12) 27% (20/74) 0.80
Presence of autoimmune 
co-morbidityc (number of patients)
15% (3/20) 5% (7/135) 0.05a
 – Antiphospholipid syndrome
 – Rheumatoid arthritis
 – Other
 – 4% (1)
 – 4% (1)
 – 4% (1)
 – 0% (0)
 – 2% (4)
 – 2% (3)
Presence of current or past viral 
infectiond
5% (1/19) 3% (4/128) 0.51
Presence of other antibodies
 – dsDNA
 – anti-nucleosomes
 – Ro52
0% (0/23)
0% (0/23)
65% (15/23)
6% (11/170)
6% (11/170)
68% (115/170)
0.37
0.37
0.82
aStatistically significant (p ≤ 0.05).
bMissing data in 55% of patients.
cMissing data in 20% of patients.
dMissing data in 24% of patients.
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using anti-human IgG peroxidase conjugate (Euroimmun) and 
stained with tetramethylbenzidine (Euroimmun) for 15  min. 
OD was determined at 450  nm (reference 620  nm) using an 
automated spectrophotometer (Spectra Mini, Tecan, Germany). 
All procedures were carried out at room temperature. The cutoff 
of the anti-Ro52 ELISA was defined at the 99% percentile based 
on samples from healthy blood donors (n = 100), anti-nuclear 
antibodies-negative patients (n =  52) and rheumatoid arthritis 
patients (n = 40). Results were evaluated semi-quantitatively as a 
ratio (OD450 sample/OD450 calibrator, ratio ≥ 1 positive).
statistics
IBM SPSS for Windows version 22 (IBM Corp., Armonk, NY, 
USA) was used for statistical analyses. Chi-square tests and 
Fisher’s exact test (categorical variables) and Mann–Whitney U 
test (continuous, non-parametric variables) were used for pair-
wise comparisons between groups. Correlations between autoan-
tibody titers and other variables (e.g., duration of storage) were 
analyzed using Spearman ranking. A 2-sided p-value of 0.05 or 
less was deemed statistically significant in this exploratory study.
resUlTs
Anti-cN-1A antibodies were found in 12% of the pSS patients 
(23/193) and in 10% of all SLE patients (26/252). The prevalence 
of anti-cN-1A showed some variation between countries in both 
diseases (Tables 1 and 2). The distribution of the levels of anti-
cN-1A antibodies did not appear to differ between the groups 
from different countries and between pSS and SLE (Figure 1).
The associations between anti-cN-1A reactivity and clinical, 
demographic, and laboratory findings are presented in Tables 1 
and 2. A trend toward gender-association of anti-cN-1A reactivity 
did not reach statistical significance (18% of men in pSS and 17% 
in SLE showed anti-cN-1A reactivity, versus 12 (p = 0.5) and 10% 
(p = 0.2), respectively, of women). No association between anti-cN-
1A and duration of disease or sample storage duration was found. 
Muscular complaints were almost equal for anti-cN-1A-positive 
and -negative patients, with myalgia being the most frequently 
reported symptom. One of the pSS patients had a biopsy-proven 
polymyositis, but this patient had no anti-cN-1A antibodies. In 
the anti-cN-1A-positive patients, a higher rate of autoimmune 
co-morbidity was seen: 15% of the anti-cN-1A-positive pSS 
and 50% of the anti-cN-1A-positive SLE patients suffered from 
one or more other autoimmune diseases, whereas autoimmune 
comorbidity was observed in 5 and 30%, respectively, of the anti-
cN-1A-negative patients (p = 0.05 in pSS, p = 0.02 in SLE). The 
presence or absence of other antibodies did not differ between the 
anti-cN-1A-positive and -negative patients in both disease groups.
DiscUssiOn
The current cohort with anti-cN-1A reactivity in 12% of pSS and 10% 
of SLE patients confirm the relatively high prevalence of anti-cN-1A 
in these diseases. In addition, a range of frequencies was observed 
in the groups from various European countries (pSS: 7–19%; SLE: 
Table 3 | Anti-cN-1A reactivity among systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) cohorts in former and current studies.
cohort Technique Origin of samples Disease number of 
patients
anti-cn-1a positivity (%)
Herbert et al. (4) ELISA with 3 synthetic peptides The Netherlands SLE 44 20
pSS 22 36
Kramp et al. (7) ELISA with recombinant full-length proteina North American SLE 33 6
pSS 20 0
Lloyd et al. (6) Immunoblotting against NT5C1A (full-length)-transfected 
and nontransfected HEK 293 cell lysates
USA SLE 96 14
pSS 44 23
Muro et al. (5) ELISA with recombinant full-length protein Japan SLE 50 6
pSS 50 4
Rietveld et al.  
(current study)
ELISA with recombinant full-length proteina Europe SLE 252 10
pSS 193 12
aThe same standardized ELISA was used in these studies.
FigUre 1 | Distribution of anti-cN-1A reactivity in primary Sjögren’s syndrome and systemic lupus erythematosus (SLE) patients from different countries. Dotted 
line = cutoff of anti-cN-1A reactivity (1.0 AU).
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6–21%), which seems to be consistent with the variation in anti-
cN-1A reactivity that was observed in these diseases in previous 
studies. However, it should be noted that the results of these studies 
were obtained with various in-house assays. Our study is the first to 
analyze anti-cN-1A in pSS and SLE patients from different centers 
in parallel using a single, standardized assay at a single laboratory. 
The current study does not offer an explanation for the relatively 
frequent presence of anti-cN-1A in pSS and SLE sera, nor for the 
variation in the frequency of anti-cN-1A among different countries.
Table  3 summarizes the results reported in four previous 
publications on anti-cN-1A reactivity in pSS and SLE. The larg-
est cohort thus far consisted of 96 SLE and 44 pSS patients and 
the study included a comparison with clinical data as well. The 
subset of SLE patients with myositis (5%) did not show anti-cN-
1A reactivity, and no correlation was found between anti-cN-1A 
reactivity and Raynaud’s phenomenon or interstitial lung disease. 
Similarly, among pSS patients no correlation could be found 
between anti-cN-1A status and clinical and laboratory features, 
and none of the pSS patients had any muscular complaints 
(6). Muro and coworkers reported concomitant positivity for 
anti-dsDNA and anti-Ro/SSA in the pSS and SLE patients with 
anti-cN-1A reactivity (5). The clinical and laboratory features of 
the two other reported cohorts are not described in detail (4, 7).
Currently, IBM diagnosis is based on the combination of clini-
cal features, laboratory findings, and muscle biopsy results (12). 
Unfortunately, application of the diagnostic criteria does not always 
lead to a quick and definite diagnosis. Although no treatment is yet 
available for IBM, a correct diagnosis is important, as for example 
misclassification as polymyositis and subsequent treatment with 
steroids can negatively influence the IBM disease course (13). The 
detection of anti-cN-1A antibodies could accelerate and improve 
the diagnosis of IBM. The presence of anti-cN-1A reactivity in a 
subset of SLE and pSS patients does not interfere with the clinical 
usefulness of anti-cN-1A testing in myositis due to the phenotypic 
differences between IBM and systemic autoimmune diseases. 
A standardized assay to detect anti-cN-1A antibodies, with clearly 
defined sensitivity and specificity, is of great importance before 
starting to use anti-cN-1A detection in clinical practice.
The large variation in the frequencies of anti-cN-1A in SLE and 
pSS reported in the aforementioned previous studies might be due to 
the different techniques that were used: western blotting and ELISA 
with the full-length recombinant protein produced in different host 
cells, and ELISA with three synthetic peptides [Table 3, reviewed in 
detail in Ref. (1, 14)]. The ELISA using three synthetic peptides is 
based on epitope mapping that has shown three regions of cN-1A 
that are targeted most frequently by autoantibodies. In that study, 
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different patterns of reactivity with these three linear epitopes were 
observed (4). However, the use of small synthetic peptides does not 
allow the detection of antibodies against discontinuous or confor-
mational epitopes. IBM sera reactive with one of these epitopes 
were not always positive when using full-length recombinant 
protein as antigen, whereas other sera were not reactive with any of 
the epitopes, but were positive when assessed using the full-length 
cN-1A ELISA (1). Variable seropositivity was seen in IBM patients 
dependent upon which isotype (IgG, IgA, or IgM) of anti-cN-1A 
antibody was tested (15, 16). In general, immunoblotting with 
full-length cN-1A expressed in transfected HEK293 cells showed 
a higher sensitivity and lower specificity than the three-peptide 
cN-1A ELISAs (1, 7). A direct comparison of the methodologies to 
detect anti-cN-1A antibodies has not yet been undertaken.
The role of cN-1A in the pathophysiology of IBM and the 
possible pathways of anti-cN-1A antibody induced pathology 
are not yet fully elucidated, although a recent study confirmed 
a role of anti-cN-1A antibodies in the onset of IBM (14, 17). 
In vitro and in  vivo (in mice) passive immunization with anti-
cN-1A–positive IgG leads to histological changes in the muscle 
fibers resembling the changes in IBM: an increase of p62 aggre-
gates and an associated macrophage infiltration was seen in the 
in vivo model (17). Whether passive immunization led to patho-
physiological changes as seen in SLE and pSS, is not stated. The 
variation in anti-cN-1A reactivity between the different countries 
included in our current study might be due to the different genetic 
backgrounds of the patients, although HLA-association studies in 
IBM did not show a difference between anti-cN-1A-positive and 
-negative patients (18).
The retrospective nature of our study led to some difficulties 
in the interpretation of the clinical data. First of all, for some 
items a large subset of data is lacking, for example regarding the 
presence or absence of muscular complaints. Furthermore, the 
presence or absence of muscular symptoms might be subject to 
reporting bias of patients: fatigue and diffuse pain in patients 
with systemic autoimmune diseases could be reported as myalgia. 
Autoimmune comorbidity might have been reported in different 
ways and antiphospholipid syndrome, for example, might not 
have been reported in a subset of patients. This means that the 
finding of an increased rate of autoimmune comorbidity in the 
anti-cN-1A-positive patients should be interpreted with caution. 
A prospective study with standardized clinical data collection and 
a broader panel of autoantibodies (including for example anti-
CCP, anti-thyroid, and anti-skin autoantibodies) should clarify 
the relationship between anti-cN-1A reactivity and the presence 
of comorbidities, in particular other autoimmune diseases. A 
former study on IBM, using standardized data extraction sheets, 
did not show such a correlation (2). The included sera were 
provided by European centers only, meaning that comparisons 
with cohorts with other ethnical backgrounds can be difficult. 
We did not test healthy subjects in parallel with the SLE and 
pSS patients, but two independent laboratories have previously 
evaluated healthy subjects using the same ELISA as we have used 
in this study, showing anti-cN-1A reactivity in 2 and 3% (1/52 
and 7/202) (7).
This retrospective study confirms the relatively high 
prevalence and substantial variation in anti-cN-1A reactivity 
in different cohorts of pSS and SLE patients. Based on this, we 
conclude that anti-cN-1A should be classified as a MAA, not as 
a MSA. Prospective studies should shed more light on the role 
of anti-cN-1A in pSS and SLE to elucidate its pathophysiological 
role and to further explore its potential correlation with clinical 
features.
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